摘要
潜在的瘢痕疙瘩发病的分子机制尚不清楚。microRNA(miRNA)是一类小型的调控RNA,已涌现出一批如转录后基因抑制因子,参与皮肤病的多种病理生理学过程。我们研究了患者血清中miRNA的表达谱去破译参与瘢痕疙瘩疾病发展的复杂因素。使用包含了人类的成熟和前体miRNA序列的miRNA芯片去表征miRNA表达谱在9例瘢痕疙瘩患者和7例正常对照组的血清中。实时定量PCR验证miRNA的表达。差异表达的miRNA的假定目标通过生物信息学进行了功能注释。miRNA芯片鉴定了37个差异表达的miRNA(17上调和20下调)在瘢痕疙瘩患者中,同健康对照相比。功能注释表明,这些差异表达的miRNA的目标在信号通路上富集,是疤痕形成和伤口愈合的必不可少的原因。miRNA的表达谱在瘢痕疙瘩患者中被改变,这为其的起始和进展的分子机制提供线索。miRNA可能部分通过影响相关的瘢痕疙瘩发病机制中的关键信号通路而导致瘢痕疙瘩。
关键词: 瘢痕疙瘩;微小核糖核酸;血清;发病病因;疤痕;病因。
Current Molecular Medicine
Title:Serum miRNAs Signature Plays an Important Role in Keloid Disease
Volume: 16 Issue: 5
Author(s): Y. Luan, Y. Liu, C. Liu, Q. Lin, F. He, X. Dong, Z. Xiao
Affiliation:
关键词: 瘢痕疙瘩;微小核糖核酸;血清;发病病因;疤痕;病因。
摘要: The molecular mechanism underlying the pathogenesis of keloid is largely unknown. MicroRNA (miRNA) is a class of small regulatory RNA that has emerged as a group of posttranscriptional gene repressors, participating in diverse pathophysiological processes of skin diseases. We investigated the expression profiles of miRNAs in the sera of patients to decipher the complicated factors involved in the development of keloid disease. MiRNA expression profiling in the sera from 9 keloid patients and 7 normal controls were characterized using a miRNA microarray containing established human mature and precursor miRNA sequences. Quantitative real-time PCR was performed to confirm the expression of miRNAs. The putative targets of differentially expressed miRNAs were functionally annotated by bioinformatics. MiRNA microarray analysis identified 37 differentially expressed miRNAs (17 upregulated and 20 downregulated) in keloid patients, compared to the healthy controls. Functional annotations revealed that the targets of those differentially expressed miRNAs were enriched in signaling pathways essential for scar formation and wound healing. The expression profiling of miRNAs is altered in the keloid, providing a clue for the molecular mechanisms underlying its initiation and progression. MiRNAs may partly contribute to the etiology of keloids by affecting the critical signaling pathways relevant to keloid pathogenesis.
Export Options
About this article
Cite this article as:
Y. Luan, Y. Liu, C. Liu, Q. Lin, F. He, X. Dong, Z. Xiao , Serum miRNAs Signature Plays an Important Role in Keloid Disease, Current Molecular Medicine 2016; 16 (5) . https://dx.doi.org/10.2174/1566524016666160429121345
DOI https://dx.doi.org/10.2174/1566524016666160429121345 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nociceptin / Orphanin FQ (NOP) Receptors as Novel Potential Target in the Treatment of Gastrointestinal Diseases
Current Drug Targets Role of Azoles in Cancer Prevention and Treatment: Present and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Biomolecules Linked to Transition Metal Complexes - New Chances for Chemotherapy
Current Medicinal Chemistry Yttrium-90 – Current Status, Expected Availability and Applications of a High Beta Energy Emitter
Current Radiopharmaceuticals Quality of Life Assessments in Colorectal Cancer Surgery. A Review
Current Cancer Therapy Reviews MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets New Issues for Copper-64: from Precursor to Innovative Pet Tracers in Clinical Oncology
Current Radiopharmaceuticals Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets
Current Drug Targets Large-Scale and Facile Synthesis of Biocompatible Yb-Based Nanoparticles as a Contrast Agent for In Vivo X-Ray Computed Tomography Imaging
Current Topics in Medicinal Chemistry Preclinical and Clinical Studies of Novel Breast Cancer Drugs Targeting Molecules Involved in Protein Kinase C Signaling, the Putative Metastasis-Suppressor Gene Cap43 and the Y-box Binding Protein-1
Current Medicinal Chemistry Erlotinib: A Targeted Anticancer Drug
Current Cancer Therapy Reviews Current Management of In Situ and Invasive Cervical Adenocarcinoma
Current Women`s Health Reviews Preclinical Evaluation of a Monoclonal Antibody (3C6) Specific for Prostate-Specific Membrane Antigen
Current Radiopharmaceuticals Antibody Engineering for Targeted Therapy of Cancer Recombinant Fv-Immunotoxins
Current Pharmaceutical Biotechnology CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry A Novel Method for Screening of Anti-Cancer Drugs: Availability of Screening in Acidic Medium
Recent Patents on Biomedical Engineering (Discontinued)